Black Diamond Therapeutics Inc - Company Profile
Powered by 
All the data and insights you need on Black Diamond Therapeutics Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Black Diamond Therapeutics Inc Strategy Report
- Understand Black Diamond Therapeutics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Black Diamond Therapeutics Inc (Black Diamond) is a precision oncology medicine company. It discovers small molecules and tumor agnostic therapies for the treatment of cancer. The company’s pipeline product candidates include BDTX- 4933 is designed to be a brain penetrant and highly selective and potent inhibitor of oncogenic BRAF Class I, II, III and active RAF dimers promoted by upstream oncogenic alterations; and BDTX-1535, a brain-penetrant small-molecule inhibitor for the treatment of glioblastoma, affecting the brain or spine. It is also developing its Mutation-Allostery-Pharmacology (MAP) technology platform, to identify oncogenic mutations that promote cancer. Black Diamond is headquartered in Cambridge, Massachusetts, the US.
Headquarters
United States of America
Address
One Main Street, 14th Floor, Cambridge, Massachusetts, 02142
Website
www.blackdiamondtherapeutics.com
Telephone
1 617 4175868
No of Employees
54
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
BDTX (NASD)
EPS
XYZ
Net Income (2022)
XYZ
9.6%
(2022 vs 2021)
Market Cap*
$261.7M
* As of and is in US$
Black Diamond Therapeutics Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| BDTX-1535: |
| Glioblastoma (GBM) |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Others | In September, the company announced the first patients dosed in mutation matched expansion cohorts of non-small cell lung cancer in the ongoing Phase 1 clinical study evaluating BDTX-1535. |
| 2022 | Regulatory Approval | In January, the company announced U.S. Food and Drug Administration (FDA) cleared an investigational new drug (IND) application for its MasterKey inhibitor BDTX-1535. |
| 2021 | Contracts/Agreements | In September, the company entered into a strategic partnership with OpenEye Scientific to expand MAP drug discovery platform. |
Competitor Comparison
| Key Parameters | Black Diamond Therapeutics Inc | AstraZeneca Plc | Daiichi Sankyo Co Ltd | Blueprint Medicines Corp | Puma Biotechnology Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United Kingdom | Japan | United States of America | United States of America |
| City | Cambridge | Cambridge | Chuo-Ku | Cambridge | Los Angeles |
| State/Province | Massachusetts | England | Tokyo | Massachusetts | California |
| No. of Employees | 54 | 89,900 | 17,435 | 655 | 185 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Mark A. Velleca, M.D., Ph.D. | Chairman; Chief Executive Officer | Executive Board | 2023 | - |
| Fang Ni | Chief Business Officer; Chief Financial Officer | Senior Management | 2021 | 35 |
| Brent Hatzis Schoch | Chief Operating Officer; General Counsel | Senior Management | 2019 | 57 |
| Elizabeth L. Montgomery | Chief People Officer | Senior Management | 2022 | - |
| Sergey Yurasov, Ph.D. | Chief Medical Officer | Senior Management | 2022 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer